Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||KIT exon 18 (amino acids 829-866) indicates an unspecified mutation has occurred in exon 18 of the KIT gene.|
|Associated Drug Resistance|
|Category Variants Paths||
KIT mutant KIT exon18
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT mutant||gastrointestinal stromal tumor||not applicable||N/A||Clinical Study||Diagnostic||KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).||25193432 26276366 25729899|
|KIT mutant||gastrointestinal stromal tumor||sensitive||Imatinib + Infigratinib||Preclinical - Pdx||Actionable||In a preclinical study, Truseltiq (infigratinib) and Gleevec (imatinib) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).||25673643|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Avapritinib||Phase I||Actionable||In a Phase I (NAVIGATOR) trial, Ayvakit (avapritinib) treatment resulted in an objective response rate of 13% (7/52, 7 partial responses) and a disease control rate of 63% (33/52) in patients with KIT-mutant gastrointestinal stromal tumor (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).||detail...|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).||detail...|
|KIT mutant||gastrointestinal stromal tumor||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) was well tolerated, resulted in an objective response in 11.3% (16/142, 16 partial responses) and stable disease in 61.3% (87/142) of patients with advanced gastrointestinal stromal tumor harboring KIT (exon 11, n=103; exon 9, n=26; other, n=6) or PDGFRA mutations (n=7), with a median progression-free survival of 5.6 months (PMID: 32804590; NCT02571036).||32804590|
|KIT mutant||melanoma||sensitive||Nilotinib||Phase II||Actionable||In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).||28843487|
|KIT mutant||melanoma||sensitive||Nilotinib||Phase II||Actionable||In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).||28327988|
|KIT mutant||melanoma||predicted - sensitive||Ripretinib||Phase I||Actionable||In a Phase I trial, Qinlock (ripretinib) treatment demonstrated manageable safety and preliminary efficacy in patients with KIT-mutated melanoma, and led to an objective response rate of 23% (6/26, 1 complete and 5 partial responses), a median progression-free survival of 7.3 months, and a median duration of response of 9.1 months (PMID: 35753087; NCT02571036).||35753087|